{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T04:15:01Z","timestamp":1773807301893,"version":"3.50.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[1989,4,1]],"date-time":"1989-04-01T00:00:00Z","timestamp":607392000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[1989,4]]},"DOI":"10.1007\/bf00439552","type":"journal-article","created":{"date-parts":[[2004,11,11]],"date-time":"2004-11-11T06:17:24Z","timestamp":1100153844000},"page":"481-488","source":"Crossref","is-referenced-by-count":18,"title":["A fixed dose study of the plasma concentration and clinical effects of thioridazine and its major metabolites"],"prefix":"10.1007","volume":"97","author":[{"given":"Bruce M.","family":"Cohen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph F.","family":"Lipinski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Waternaux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"CR1","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/BF00427315","volume":"85","author":"G Alfredsson","year":"1985","unstructured":"Alfredsson G, H\u00e4rnyd C, Wiesel F-A (1985) Effects of sulpiride and chlorpromazine on autistic and positive psychotic symptoms in schizophrenic patients?relationship to drug concentrations. Psychopharmacology 85:8?13.","journal-title":"Psychopharmacology"},{"key":"CR2","first-page":"587","volume":"21","author":"R Axelsson","year":"1977","unstructured":"Axelsson R (1977) On the serum concentrations and antipsychotic effects of thioridazine, thioridazine side-chain sulfoxide and thioridazine side-chain sulfone, in chronic psychotic patients. Curr Ther Res 21:587.","journal-title":"Curr Ther Res"},{"key":"CR3","first-page":"242","volume":"19","author":"R Axelsson","year":"1976","unstructured":"Axelsson R, Martensson E (1976) Serum concentration and elimination from serum of thioridazine in psychiatric patients. Curr Ther Res 19:242?265.","journal-title":"Curr Ther Res"},{"key":"CR4","first-page":"561","volume":"20","author":"R Axelsson","year":"1977","unstructured":"Axelsson R, Martensson E (1977) The concentration pattern of nonconjugated thioridazine metabolites in serum by thioridazine treatment and its relationship to physiological and clinical variables. Curr Ther Res 20:561?586.","journal-title":"Curr Ther Res"},{"key":"CR5","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1176\/ajp.141.6.748","volume":"141","author":"RJ Baldessarini","year":"1984","unstructured":"Baldessarini RJ, Katz B, Cotten P (1984) Dissimilar dosing with high-potency and low-potency neuroleptics. Am J Psychiatry 141:748?752.","journal-title":"Am J Psychiatry"},{"key":"CR6","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1001\/archpsyc.1988.01800250095013","volume":"45","author":"RJ Baldessarini","year":"1988","unstructured":"Baldessarini RJ, Cohen BM, Teicher MH (1988) Significance of neuroleptic dose and plasma level in the pharmacologic treatment of psychoses. Arch Gen Psychiatry 45:79?91.","journal-title":"Arch Gen Psychiatry"},{"key":"CR7","first-page":"246","volume-title":"Guidelines for the use of psychotropic drugs","author":"BM Cohen","year":"1983","unstructured":"Cohen BM (1983) The clinical utility of plasma neuroleptic levels. In: Stancer HC, Garfinkel PE, Rakoff VM (eds) Guidelines for the use of psychotropic drugs. Spectrum, Jamaica New York, pp 246?260."},{"key":"CR8","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/978-3-642-73280-5_5","volume-title":"Current trends in psychopharmacology","author":"BM Cohen","year":"1988","unstructured":"Cohen BM (1988) Neuroleptic drugs in the treatment of acute psychosis. In: Casey DE, Christensen AV (eds) Current trends in psychopharmacology. Springer, Berlin Heidelberg New York Tokyo, pp 47?61."},{"key":"CR9","first-page":"199","volume-title":"Neuroreceptors?basic and clinical aspects","author":"BM Cohen","year":"1981","unstructured":"Cohen BM, Lipinski JF (1981) Radioreceptor assays of blood levels of neuroleptics. In: Usdin E (ed) Neuroreceptors?basic and clinical aspects. Wiley, New York, pp 199?214."},{"key":"CR10","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0033-3182(86)72733-3","volume":"S27","author":"BM Cohen","year":"1986","unstructured":"Cohen BM, Lipinski JF (1986) Treatment of acute psychosis with non-neuroleptic agents. Psychosomatics S27:7?16.","journal-title":"Psychosomatics"},{"key":"CR11","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0165-1781(79)90062-3","volume":"1","author":"BM Cohen","year":"1979","unstructured":"Cohen BM, Herschel M, Aoba A (1979) Neuroleptic, antimuscarinic, and antiadrenergic activity of chlorpromazine, thioridazine, and their metabolites. Psychiatr Res, 1:199?208.","journal-title":"Psychiatr Res"},{"key":"CR12","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/0028-3908(80)90041-6","volume":"19","author":"BM Cohen","year":"1980","unstructured":"Cohen BM, Herschel M, Miller EM, Baldessarini RJ (1980a) Radioreceptor assay of haloperidol tissue levels in the rat. Neuropharmacology 19:663?668.","journal-title":"Neuropharmacology"},{"key":"CR13","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/BF00435313","volume":"70","author":"BM Cohen","year":"1980","unstructured":"Cohen BM, Lipinski JF, Pope HG, Harris PQ, Altesman RI (1980b) Neuroleptic blood levels of patients on thioridazine and clinical improvement. Psychopharmacology 70:191?194.","journal-title":"Psychopharmacology"},{"key":"CR14","doi-asserted-by":"crossref","first-page":"A15","DOI":"10.1097\/00004714-198510000-00001","volume":"5","author":"TB Cooper","year":"1985","unstructured":"Cooper TB (1985) Neuroleptic drug monitoring and radioreceptor assays. J Clin Psychopharmacol 5:A15-A16.","journal-title":"J Clin Psychopharmacol"},{"key":"CR15","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/270180a0","volume":"270","author":"I Creese","year":"1977","unstructured":"Creese I, Snyder SH (1977) A novel, simple and sensitive radioreceptor assay for antischizophrenic drugs in blood. Nature 270:180?182.","journal-title":"Nature"},{"key":"CR16","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/00004714-198510000-00003","volume":"5","author":"SH Curry","year":"1985","unstructured":"Curry SH (1985) Commentary: the strategy and value of neuroleptic drug monitoring. J Clin Psychopharmacol 5:263?271.","journal-title":"J Clin Psychopharmacol"},{"key":"CR17","first-page":"905","volume-title":"Psychopharmacology: a generation of progress","author":"JM Davis","year":"1978","unstructured":"Davis JM, Erickson SE, Dekirmenjian H (1978) Plasma levels of antipsychotic drugs and clinical response. In: Lipton MA, DiMascio A, Killam KF (eds) Psychopharmacology: a generation of progress. Raven Press, New York, pp 905?916."},{"key":"CR18","first-page":"503","volume":"50","author":"J Delay","year":"1952","unstructured":"Delay J, Deniker P (1952) 38 Cas de psychoses trait\u00e9s par la cure prolong\u00e9e et continue de 4560 R.P.C.R. Congr\u00e8s. M\u00e9d Ali\u00e9n Neurol France 50:503?518.","journal-title":"M\u00e9d Ali\u00e9n Neurol France"},{"key":"CR19","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/00004714-198406000-00004","volume":"4","author":"DL Garver","year":"1984","unstructured":"Garver DL, Hirschowitz J, Glicksteen GA, Kanter DR, Mauroidis ML (1984) Haloperidol plasma and red blood cell levels and clinical antipsychotic response. J Clin Psychopharmacol 4:133?137.","journal-title":"J Clin Psychopharmacol"},{"key":"CR20","first-page":"171","volume-title":"Pharmacokinetics of psychotic drugs. S.P.","author":"LA Gottschalk","year":"1976","unstructured":"Gottschalk LA, DiNovo E, Biener R, Birch H, Syben M, Noble EP (1976) Plasma levels of mesoridazine and its metabolites and clinical response in acute schizophrenia after a single intramuscular drug dose. In: Gottschalk LA, Merlis S (eds) Pharmacokinetics of psychotic drugs. S.P. Medical Books, New York, pp 171?189."},{"key":"CR21","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/BF00432245","volume":"27","author":"CB Hansen","year":"1982","unstructured":"Hansen CB, Larsen N-E, Gulmann N (1982) Dose-response relationship of perphenazine in the treatment of acute psychoses. Psychopharmacology 27:112?115.","journal-title":"Psychopharmacology"},{"key":"CR22","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1093\/schbul\/13.1.133","volume":"13","author":"JM Kane","year":"1987","unstructured":"Kane JM (1987) Treatment of schizophrenia. Schizophren Bull 13:133?156.","journal-title":"Schizophren Bull"},{"key":"CR23","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1001\/archpsyc.1983.01790090075012","volume":"40","author":"GA Keepers","year":"1983","unstructured":"Keepers GA, Clappison VJ, Casey DE (1983) Initial anticholinergic prophylaxis for neuroleptic-induced extrapyramidal syndromes. Arch Gen Psychiatry 40:1113?1117.","journal-title":"Arch Gen Psychiatry"},{"key":"CR24","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S0378-4347(00)81862-9","volume":"231","author":"CD Kilts","year":"1982","unstructured":"Kilts CD, Patrick KS, Breese GR, Mailman RB (1982) Simultaneous determination of thioridazine and its S-oxidized and N-demethylated metabolites using high-performance liquid chromatography on radially compressed silica. J Chromatogr 231:377?391.","journal-title":"J Chromatogr"},{"key":"CR25","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/BF00381354","volume":"234","author":"P Linkowski","year":"1984","unstructured":"Linkowski P, Hubain P, von Frenckell R, Mendlewicz J (1984) Haloperidol plasma levels and clinical response in paranoid schizophrenics. Eur Arch Psychiatry Neurol Sci 234:231?236.","journal-title":"Eur Arch Psychiatry Neurol Sci"},{"key":"CR26","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1600-0773.1982.tb00935.x","volume":"50","author":"M Linnoila","year":"1982","unstructured":"Linnoila M, Rosenblatt JE, Jeste D, Skinner T, Potter WZ, Wyatt RJ (1982) Disparate serum thioridazine concentrations: liquid chromatography versus radioreceptor assay. Acta Pharmacol Toxicol 50:25?29.","journal-title":"Acta Pharmacol Toxicol"},{"key":"CR27","first-page":"833","volume":"19","author":"RB Mailman","year":"1984","unstructured":"Mailman RB, Pierce FP, Crofton KM, Petitto J, De Haven DL, Kilts CO, Lewis MH (1984) Thioridazine and the neuroleptic radioreceptor assay. Biol Psychiatry 19:833?847.","journal-title":"Biol Psychiatry"},{"key":"CR28","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/BF00427577","volume":"81","author":"ML Mavroidis","year":"1983","unstructured":"Mavroidis ML, Kanter DR, Hirschowitz J, Garver DL (1983) Clinical response and plasma haloperidol levels in schizophrenia. Psychopharmacology 81:354?356.","journal-title":"Psychopharmacology"},{"key":"CR29","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1001\/archpsyc.1978.01770330055004","volume":"35","author":"PRA May","year":"1978","unstructured":"May PRA, Van Putten T (1978) Plasma levels of chlorpromazine in schizophrenia: a critical review of the literature. Arch Gen Psychiatry 35:1081?1087.","journal-title":"Arch Gen Psychiatry"},{"key":"CR30","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1001\/archpsyc.1981.01780270088012","volume":"38","author":"PRA May","year":"1981","unstructured":"May PRA, Van Puten T, Jenden DJ (1981) Chlorpromazine levels and the outcome of treatment in schizophrenic patients. Arch Gen Psychiatry 38:202?207.","journal-title":"Arch Gen Psychiatry"},{"key":"CR31","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/00004714-198606000-00001","volume":"6","author":"JP McEvoy","year":"1986","unstructured":"McEvoy JP, Stiller RL, Farr R (1986) Plasma haloperidol levels drawn at neuroleptic threshold doses: a pilot study. J Clin Psychopharmacol 6:133?138.","journal-title":"J Clin Psychopharmacol"},{"key":"CR32","first-page":"256","volume":"3","author":"G McKay","year":"1985","unstructured":"McKay G, Cooper JK, Gurnsey T, Midha KK (1985) A simple, sensitive, and simultaneous assay of thioridazine, sulforidazine, and mesoridazine in plasma by HPLC. Liq Chromatogr 3:256?279.","journal-title":"Liq Chromatogr"},{"key":"CR33","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1007\/BF00449123","volume":"76","author":"MA Moulin","year":"1982","unstructured":"Moulin MA, Davy JP, Debruyne D, Andersson JC, Bigot MC, Camsonne R, Poilpr\u00e9 E (1982) Serum levels monitoring and therapeutic effect of haloperidol in schizophrenic patients. Psychopharmacology 76:346?350.","journal-title":"Psychopharmacology"},{"key":"CR34","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1176\/ajp.137.8.921","volume":"137","author":"HG Pope","year":"1980","unstructured":"Pope HG, Lipinski JF, Cohen BM, Axelrod D (1980) Schizoaffective disorder: an invalid diagnosis? Am J Psychiatry 137:921?927.","journal-title":"Am J Psychiatry"},{"key":"CR35","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1002\/cpt1972136931","volume":"13","author":"G Sakalis","year":"1972","unstructured":"Sakalis G, Curry SH, Mould GP, Lader MH (1972) Physiologic and clinical effects of chlorpromazine and their relationship to plasma level. Clin Pharmacol Ther 13:931?946.","journal-title":"Clin Pharmacol Ther"},{"key":"CR36","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1001\/archpsyc.1980.01780220095011","volume":"37","author":"Y Sakurai","year":"1980","unstructured":"Sakurai Y, Takahashi R, Nakahara T, Ikenaga H (1980) Prediction of response to and actual outcome of chlorpromazine treatment in schizophrenic patients. Arch Gen Psychiatry 37:1057?1062.","journal-title":"Arch Gen Psychiatry"},{"key":"CR37","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/261717a0","volume":"261","author":"P Seeman","year":"1976","unstructured":"Seeman P, Lee T, Chau-Wong M, Wong K (1976) Antipsychotic drug doses and neuroleptic dopamine receptors. Nature 261:717?719.","journal-title":"Nature"},{"issue":"5:2","key":"CR38","first-page":"22","volume":"46","author":"GM Simpson","year":"1985","unstructured":"Simpson GM, Yadalam K (1985) Blood levels of neuroleptics: the state of the art. J Clin Psychiatry 46(5:2):22?28.","journal-title":"J Clin Psychiatry"},{"key":"CR39","first-page":"52","volume":"21","author":"RC Smith","year":"1985","unstructured":"Smith RC, Baumgartner R, Burd A, Ravichandran GK, Mauldin M (1985) Haloperidol and thioridazine drug levels and clinical response in schizophrenia: comparison of gas-liquid chromatography and radioreceptor drug level assay. Psychopharmacol Bull 21:52?58.","journal-title":"Psychopharmacol Bull"},{"key":"CR40","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0378-4347(00)84122-5","volume":"307","author":"AL Stoll","year":"1984","unstructured":"Stoll AL, Baldessarini RJ, Cohen BM, Finklestein SP (1984) Assay of plasma thioridazine and metabolites by high performance liquid chromatography with amperometric detection. J Chromatogr Biomed Appl 307:457?463.","journal-title":"J Chromatogr Biomed Appl"},{"key":"CR41","first-page":"201","volume":"23","author":"T Putten Van","year":"1987","unstructured":"Van Putten T, Marder SR, Mintz J (1987) The therapeutic index of haloperidol in newly admitted schizophrenic patients. Psychopharmacol Bull 23:201?205.","journal-title":"Psychopharmacol Bull"},{"key":"CR42","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/BF00562905","volume":"11","author":"FAJ Vanderheeren","year":"1977","unstructured":"Vanderheeren FAJ, Muusze RG (1977) Plasma levels and half-lives of thioridazine and some of its metabolites. Eur J Clin Pharmacol 11:135?140.","journal-title":"Eur J Clin Pharmacol"},{"key":"CR43","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/00004714-198702000-00005","volume":"7","author":"J Volavka","year":"1987","unstructured":"Volavka J, Cooper TB (1987) Review of haloperidol blood level and clinical response: looking through the window. J Clin Psychopharmacol 7:25?30.","journal-title":"J Clin Psychopharmacol"},{"key":"CR44","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1176\/ajp.138.10.1307","volume":"138","author":"M Wahba","year":"1981","unstructured":"Wahba M, Donlon PT, Meadow A (1981) Cognitive changes in acute schizophrenia with brief neuroleptic threatment. Am J Psychiatry 138:1307?1310.","journal-title":"Am J Psychiatry"},{"key":"CR45","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/j.1600-0447.1982.tb00308.x","volume":"66","author":"J-E Widerlov","year":"1982","unstructured":"Widerlov J-E, H\u00e4ggstr\u00f6m CD, Kilts CD, Andersson U, Breese GR, Mailman RB (1982) Serum concentrations of thioridazine, its major metabolites and serum neuroleptic-like activities in schizophrenics with and without tardive dyskinesia. Acta Psychiatr Scand 66:294?305.","journal-title":"Acta Psychiatr Scand"},{"key":"CR46","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1600-0447.1978.tb06929.x","volume":"58","author":"B Wode-Helgodt","year":"1978","unstructured":"Wode-Helgodt B, Borg S, Fryo B, Sedvall G (1978) Clinical effects and drug concentrations in plasma and cerebrospinal fluid in psychotic patients treated with fixed doses of chlorpromazine. Acta Psychiatr Scand 58:149?173.","journal-title":"Acta Psychiatr Scand"},{"key":"CR47","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1001\/archpsyc.1983.01790030071009","volume":"40","author":"JA Yesavage","year":"1983","unstructured":"Yesavage JA, Holman CA, Cohn R, Lombozo L (1983) Correlation of initial thiothixene serum levels and clinical response. Arch Gen Psychiatry 40:301?304.","journal-title":"Arch Gen Psychiatry"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00439552.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF00439552\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00439552","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,3]],"date-time":"2019-04-03T20:37:26Z","timestamp":1554323846000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF00439552"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1989,4]]},"references-count":47,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1989,4]]}},"alternative-id":["BF00439552"],"URL":"https:\/\/doi.org\/10.1007\/bf00439552","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[1989,4]]}}}